Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 2, 2009, Pages 147-157

  Majeed, Farhan ^a   Kop, Willem J ^a   Poston, Robert S ^b   Kallam, Seeta ^b   Mehra, Mandeep R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PROTHROMBIN ACTIVATION FRAGMENT 1.2; SPIRONOLACTONE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; OBSERVATIONAL STUDY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM;

ADULT; AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; DRUG RESISTANCE; FEMALE; FIBRINOLYSIS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTHROMBIN; RISK ASSESSMENT; THROMBELASTOGRAPHY; THROMBOEMBOLISM; TIME FACTORS;

EID: 59549085225     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1441     Document Type: Article

References (36)

1. Rose EA et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435-1443
2. Deng MC et al.; International Society for Heart and Lung Transplantation (2005) Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third annual report-2005. J Heart Lung Transplant 24: 1182-1187
3. Tsukui H et al. (2007) Cerebrovascular accidents in patients with a ventricular assist device. J Thorac Cardiovasc Surg 134 114-123
4. Houel R et al. (2003) Resistance to aspirin after external ventricular assist device implantation. J Thorac Cardiovasc Surg 126: 1636-1637
5. Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110: E489-e493
6. Cotter G et al. (2004) Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 147: 293-300
7. Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817
8. Kurth T et al. (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108: 1191-1195
9. Hung J et al. (1995) Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92: 2432-2436
10. Cipollone F et al. (2004) Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24: 246-255
11. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104: 2666-2672
12. A polymorphisms display different sensitivities to agonists. Circulation 101 1013-1018
13. Larsson PT et al. (1994) Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 89: 1951-1957
14. Kawasaki T et al. (2000) Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31: 591-595
15. Marshall PW et al. (1997) A comparison of the effects of aspirin on bleeding time measured using the Simplate™ method and closure time measured using the PFA-100™, in healthy volunteers. Br J Clin Pharmacol 44: 151-155
16. Mueller MR et al. (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78: 1003-1007
17. Grundmann K et al. (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250: 63-66
18. Gum PA et al. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230-235
19. Zimmermann N et al. (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108: 542-547
20. Eikelboom JW et al. (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655
21. Sane DC et al. (2002) Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 90: 893-895
22. Houël R et al. (2004) Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 128: 197-202
23. Dyszkiewicz-Korpanty AM et al. (2005) Approach to the assessment of platelet function: Comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11: 25-35
24. Ivandic BT et al. (2007) Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 53: 614-619
25. Poston RS et al. (2006) Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 81: 104-110
26. Aggrolink software version 5.2.1 (Chrono-Log Corp, Haverton, PA)
27. Luddington RJ (2005) Thrombelastography/thromboelastometry. Clin Lab Haematol 27: 81-90
28. Bochsen L et al. (2007) Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 5: 3
29. Feinberg WM et al. (1999) Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 30: 2547-2553
30. Johansson L et al. (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/ plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31: 26-32
31. Haude M et al. (1995) Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2. Am Heart J 130: 228-238
32. Lazar RM et al. (2004) Neurological events during long-term mechanical circulatory support for heart failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 109: 2423-2427
33. Thygesen K et al.; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007) Universal definition of myocardial infarction. J Am Coll Cardiol 50: 2173-2195
34. Beppu S et al. (1992) High incidence of left ventricular thrombosis and systemic embolism in patients with left ventricular assist system [Japanese]. J Cardiol 22: 713-720
35. Fries D et al. (2003) Coagulation monitoring and management of anticoagulation during cardiac assist device support. Ann Thorac Surg 76: 1593-1597
36. Spanier T et al. (1996) Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 112: 1090-1097